These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

520 related items for PubMed ID: 19166708

  • 21. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP, Saseen JJ.
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond.
    Cohen M.
    Catheter Cardiovasc Interv; 2009 Oct 01; 74(4):579-97. PubMed ID: 19472347
    [Abstract] [Full Text] [Related]

  • 25. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices.
    Faxon DP.
    Rev Cardiovasc Med; 2005 Oct 01; 6 Suppl 4():S3-14. PubMed ID: 17710074
    [Abstract] [Full Text] [Related]

  • 26. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
    Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, Braunwald E, Gibson CM, TIMI Study Group.
    Am Heart J; 2009 Sep 01; 158(3):e21-6. PubMed ID: 19699846
    [Abstract] [Full Text] [Related]

  • 27. Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes.
    Alagona P.
    J Invasive Cardiol; 2010 Jan 01; 22(1):40-4. PubMed ID: 20048399
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Dual antiplatelet drug resistance in patients with acute coronary syndrome.
    Guha S, Sardar P, Guha P, Roy S, Mookerjee S, Chakrabarti P, Deb PK, Chaudhuri U, Deb S, Karmakar R, Dasgupta AK, Lahiri P.
    Indian Heart J; 2009 Jan 01; 61(1):68-73. PubMed ID: 19729693
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes.
    Depta JP, Cannon CP, Fonarow GC, Zhao X, Peacock WF, Bhatt DL, Get With The Guidelines Steering Committee and Investigators.
    Am J Cardiol; 2009 Nov 01; 104(9):1171-8. PubMed ID: 19840557
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
    Ivandic BT, Kurz K, Keck F, Staritz P, Lehrke S, Katus HA, Giannitsis E.
    Thromb Haemost; 2008 Oct 01; 100(4):648-54. PubMed ID: 18841288
    [Abstract] [Full Text] [Related]

  • 39. Clopidogrel: an updated and comprehensive review.
    Fox KA, Chelliah R.
    Expert Opin Drug Metab Toxicol; 2007 Aug 01; 3(4):621-31. PubMed ID: 17696811
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.